uniQure (NASDAQ:QURE) is a clinical-stage biotechnology company focused on developing gene therapies. The company is gaining attention from analysts due to its promising drug development milestones. On March 9, 2026, Daniil Gataulin from Chardan Capital set a price target of $31 for QURE, suggesting a potential increase of approximately 72.32% from its current price of $17.99.
Wall Street analysts are increasingly interested in uniQure, as highlighted by 24/7 Wall St., due to its significant drug development milestones. RBC Capital's Luca Issi upgraded the stock to Outperform, raising the price target to $35 from $11. Wells Fargo also upgraded QURE to Overweight, setting a price target of $60. These upgrades reflect optimism about uniQure's potential.
A key factor influencing these upgrades is the departure of Vinay Prasad from the FDA. RBC Capital suggests this change could lead to a more balanced discussion on the risk and reward associated with uniQure's Huntington's disease treatment. This shift may result in a more favorable regulatory stance, boosting investor confidence in the company's prospects.
Currently, QURE is priced at $17.99, showing a significant increase of 26.07% with a change of $3.72. The stock has fluctuated between a low of $16.03 and a high of $18.20 today. Over the past year, it reached a high of $71.50 and a low of $7.76. With a market capitalization of approximately $1.11 billion, QURE is drawing attention from investors.
The trading volume for QURE today is 15,334,548 shares, indicating strong investor interest. As the company approaches key drug development milestones, analysts believe there is substantial upside potential. The market has not fully accounted for uniQure's chances of success, making it an attractive investment opportunity.
